Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2011 - 2024)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Short term Debt of $2.8 million for Q4 2024, up 20.0% year-over-year from $2.4 million in Q1 2024, and little changed quarter-over-quarter from $2.8 million in Q3 2024.
Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2011 - 2024) Analysis & Trends
Tonix Pharmaceuticals Holding's Short term Debt history runs 3 years deep, the most recent figure standing at $2.8 million for Q4 2024.
- In Q4 2024, Short term Debt rose 20.0% year-over-year to $2.8 million; the TTM figure through Dec 2024 stood at $2.8 million (up 20.0% YoY), while the FY2024 annual figure was $2.8 million, up 20.0% from the prior year.
- Short term Debt for Q4 2024 stood at $2.8 million, roughly flat from $2.8 million in the prior quarter.
- The five-year high for Short term Debt was $2.8 million in Q1 2024, with the low at $2.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 2.82 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 2.35 Mn |
| Dec 31, 2011 | 150,000.00 |
| Sep 30, 2011 | 10,000.00 |